Browse > Article
http://dx.doi.org/10.7841/ksbbj.2012.27.3.186

Characterization of HEK293 and Namalwa Cell Cultures by Using Design of Experiment  

Kang, Kyung-Ho (Department of Biological Engineering, Inha University)
Seo, Joon-Serk (Department of Biological Engineering, Inha University)
Kim, Dong-Il (Department of Biological Engineering, Inha University)
Publication Information
KSBB Journal / v.27, no.3, 2012 , pp. 186-194 More about this Journal
Abstract
Various human host cell lines, which are more effective than the other original human cell lines, have been developed and used. Highly efficient human cell line can be obtained from the fusion between human embryonic kidney 293 (HEK293) and human Burkitt's lymphoma cells (Namalwa). Fused cell line has the advantages of both cell lines such as the high transfection efficacy of HEK293 cells and the constitutive expression of Epstein-Barr virus (EBV) genome which is related with high expression of target protein and anti-apoptotic growth of Namalwa cells. In this study, characterization of two original cell lines was performed by using design of experiment (DOE) considering cell maintenance, media development, optimization of culture condition, and scale-up. The formation of aggregates was apparent with high glutamine concentration at more than 6 mM. Supplementation of hydrolysates showed positive effects on the growth performances of HEK293 cells. On the contrary, Namalwa cells showed negative results. It was confirmed that Namalwa cells were more sensitive to lower temperature at $35^{\circ}C$ and hyperosmotic condition over 260 mOsm/kg. In addition, both cell lines showed limited growth in 3-L bioreactor due to shear stress.
Keywords
Human cell line; HEK293; Namalwa; design of experiment;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Shen, C. F. and A. Kamen (2012) Hyperosmotic pressure on HEK 293 cells during the growth phase, but not the production phase, improves adenovirus production. J. Biotechnol. 157: 228-236.   DOI
2 Liu, H., X. M. Lou, B. C. Wu, L. L. Ye, X. P. Ni, Q. W. Wang, and Z. L. Chen (2006) Effects of hydrodynamics on aggregates formation, growth and metabolism of HEK 293 cells in suspension culture. Chin. J. Biotechnol. 22: 101-106.   DOI
3 Sunley, K. and M. Butler (2010) Strategies for the enhancement of recombinant protein production from mammalian cells by growth arrest. Biotechnol. Adv. 28: 385-394.   DOI
4 Hosoi, S., H. Miyaji, M. Satoh, T. Kurimoto, A. Mihara, N. Fujiyoshi, S. Itoh, and S. Sato (1991) Optimization of cell culture conditions for production of biologically active proteins. Cytotechnology 5: 17-34.   DOI   ScienceOn
5 Hosoi, S., K. Murosumi, K. Sasaki, M. Satoh, H. Miyaji, S. Itoh, T. Tamaoki, and S. Sato (1991) Optimization of cell culture conditions for G-CSF (granulocyte-colony stimulating factor) production by genetically engineered Namalwa KJM-1 cells. Cytotechnology 7: 25-32.   DOI   ScienceOn
6 Heath, C. and R. Kiss (2007) Cell culture process development: advances in process engineering. Biotechnol. Prog. 23: 46-51.   DOI
7 Bollin, F., V. Dechavanne, and L. Chevalet (2011) Design of experiment in CHO and HEK transient transfection condition optimization. Protein Expr. Purif. 78: 61-68.   DOI
8 Kim, J. Y., Y. G. Kim, Y. K. Han, H. S. Choi, Y. H. Kim, and G. M. Lee (2011) Proteomic understanding of intracellular respones of recombinant chinese hamster ovary cells cultivated in serumfree medium supplemented with hydrolysates. Appl. Microbiol. Biotechnol. 89: 1917-1928.   DOI
9 Snee, R. D. (2011) Think strategically for design of experiments success. Bioprocess Int. 3: 18-25.
10 Liu, X., L. Zhao, Y. Wang, X. Zhang, and W. S. Tan (2010) Effects of calcium ion on adenovirus production with high densities of HEK293 cells. Biotechnol. Bioprocess. Eng. 15: 414-420.   DOI
11 Klein, G., E. Klein, and E. Kashuba (2010) Interaction of epsteinbarr virus (EBV) with human B-lymphocytes. Biochem. Biophys. Res. Commun. 396: 67-73.   DOI
12 Rajendra, Y., D. Kiseljak, L. Baldi, D. L. Hacker, and F. M. Wurm (2012) Reduced glutamine concentration improves protein production in growth-arrested CHO-DG44 and HEK-293E cells. Biotechnol. Lett. 34: 619-626.   DOI
13 Cho, M. S., H. Yee, C. Brown, B. Mei, C. Mirenda, and S. Chan (2003) Versatile expression system for rapid and stable production of recombinant proteins. Biotechnol. Prog. 19: 229-232.   DOI
14 Mei, B., Y. Chen, J. Chen, C. Q. Pan, and J. E. Murphy (2006) Expression of human coagulation factor VIII in a human hybrid cell line, HKB11. Mol. Biotechnol. 34: 165-178.   DOI
15 Durocher, Y. and M. Butler (2009) Expression systems for therapeutic glycoprotein production. Curr. Opin. Biol. 20: 700-707.   DOI
16 van Berkel, P. H. C., J. Gerritsen, E. V. Voskuilen, G. Perdok, T. Vink, J. G. J. van de Winkel, and P. W. H. I. Parren (2010) Rapid production of recombinant human IgG with improved ADCC effector function in a transient expression system. Biotechnol. Bioeng. 105: 350-357.   DOI
17 Feng, L. I., X. Joe, X. Yang, T. Tressel, and B. Lee (2005) Current therapeutic antibody production and process optimization. Bioprocessing J. 4: 1-8.
18 Wurm, F. M. (2004) Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol. 22: 1393-1398.   DOI
19 Durrani, A., A. Ali, S. Durrani, J. B. Shaikh, A. Upadhyay, and Z. H. Khan (2011) Non-animal peptone for serum free cultivation of recombinant mammalian and animal cells. Int. J. Biol. 3: 140-145.
20 Carrier, T., L. Donahue-Hjelle, and M. K. Stramaglia (2009) Banking parental cells according to cGMP guidelines. Bioprocess Int. 12: 20-25.
21 Pham, P. L., S. Perret, B. Cass, E. Carpentier, G. St-Laurent, L. Bisson, A. Kamen, and Y. Durocher (2005) Transient gene expression in HEK293 cells: peptone addition posttransfection improves recombinant protein synthesis. Biotechnol. Bioeng. 90: 332-344.   DOI
22 Cho, M. S., H. Yee, and S. Chan (2002) Establishment of a human somatic hybrid cell line for recombinant protein production. J. Biomed. Sci. 9: 631-638.   DOI
23 Butler, M. (2005) Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals. Appl. Microbiol. Biotechnol. 68: 283-291.   DOI